Published in Brain Behav Immun on May 06, 2015
The relationship of cognitive performance to concurrent symptoms, cancer- and cancer-treatment-related variables in women with early-stage breast cancer: a 2-year longitudinal study. J Cancer Res Clin Oncol (2016) 0.79
Fatigue is associated with inflammation in patients with head and neck cancer before and after intensity-modulated radiation therapy. Brain Behav Immun (2015) 0.76
Leptin-LepRb Expressed in Gastric Cancer Patients and Related to Cancer-Related Depression. Biomed Res Int (2017) 0.75
Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model. Oncotarget (2016) 0.75
Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer. Exp Toxicol Pathol (2016) 0.75
A murine model of peripheral irradiation-induced fatigue. Behav Brain Res (2016) 0.75
Inflammation and cancer. Nature (2002) 53.78
From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci (2008) 15.90
NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer (2002) 11.39
Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry (2009) 8.74
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med (2003) 7.86
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis (2009) 7.55
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med (2009) 7.06
The molecular neurobiology of depression. Nature (2008) 6.51
Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry (2005) 4.81
Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) (1998) 4.31
Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry (2014) 4.20
The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol (2007) 3.95
What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. Thorax (2005) 3.66
Cachexia in cancer patients. Nat Rev Cancer (2002) 3.63
Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun (2010) 3.37
Is late diagnosis of lung cancer inevitable? Interview study of patients' recollections of symptoms before diagnosis. Thorax (2005) 3.34
Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry (2006) 3.33
The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev (2008) 3.33
Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry (2008) 3.28
Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology (2002) 3.24
Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun (2007) 2.75
The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process (2011) 2.74
Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry (2007) 2.66
Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci U S A (1992) 2.55
Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res (2014) 2.51
Brain-immune communication pathways. Brain Behav Immun (2007) 2.50
Depression, immunity, and survival in patients with hepatobiliary carcinoma. J Clin Oncol (2007) 2.49
Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer (2003) 2.48
Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol (2012) 2.37
Are inflammatory cytokines the common link between cancer-associated cachexia and depression? J Support Oncol (2005) 2.27
Symptoms of ovarian cancer. Obstet Gynecol (2001) 2.27
Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol (2007) 2.10
Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer (2005) 2.09
Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc (2003) 2.00
IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry (2005) 1.98
'Chemobrain' in breast carcinoma?: a prologue. Cancer (2004) 1.98
Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat (2007) 1.95
Cancer-related inflammation. J Clin Immunol (2012) 1.91
A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation (2004) 1.87
Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance. J Natl Cancer Inst (2013) 1.86
Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res (2005) 1.84
Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer (2003) 1.80
Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer (2005) 1.79
Induction of IDO by bacille Calmette-Guérin is responsible for development of murine depressive-like behavior. J Immunol (2009) 1.77
The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer (2005) 1.76
Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer (2004) 1.73
Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol (2003) 1.71
Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction. Ann N Y Acad Sci (2012) 1.67
Early symptoms of ovarian cancer: a case-control study without recall bias. Fam Pract (2005) 1.65
Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Res (2005) 1.63
Selective effects of peripheral lipopolysaccharide administration on contextual and auditory-cue fear conditioning. Brain Behav Immun (1998) 1.62
Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer (2007) 1.62
Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models. Stress (2009) 1.61
Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol (2008) 1.56
Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. Gynecol Oncol (2003) 1.55
Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int J Oncol (2002) 1.53
Time course and localization patterns of interleukin-1beta messenger RNA expression in brain and pituitary after peripheral administration of lipopolysaccharide. Neuroscience (1998) 1.51
Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer (1994) 1.50
Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1. Proc Natl Acad Sci U S A (1992) 1.49
Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer (1999) 1.48
Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst (2003) 1.46
Bacille Calmette-Guérin inoculation induces chronic activation of peripheral and brain indoleamine 2,3-dioxygenase in mice. J Infect Dis (2005) 1.45
Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer (2002) 1.44
Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res (1990) 1.42
Cancer-related fatigue: links with inflammation in cancer patients and survivors. Brain Behav Immun (2007) 1.42
Brain white matter structural properties predict transition to chronic pain. Pain (2013) 1.41
Depression and immunity: a role for T cells? Brain Behav Immun (2009) 1.40
Molecular basis of sickness behavior. Ann N Y Acad Sci (1998) 1.39
Translational approaches to treatment-induced symptoms in cancer patients. Nat Rev Clin Oncol (2012) 1.38
Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse. BMC Cancer (2010) 1.38
Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med (2012) 1.37
The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms. Biol Res Nurs (2006) 1.37
The enzyme indoleamine 2,3-dioxygenase is induced in the mouse brain in response to peripheral administration of lipopolysaccharide and superantigen. Brain Behav Immun (2002) 1.35
Prognostic value of tumour necrosis and host inflammatory responses in colorectal cancer. Br J Surg (2011) 1.33
Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer (2002) 1.33
Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol (2000) 1.33
Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem (2003) 1.31
Inoculation of Bacillus Calmette-Guerin to mice induces an acute episode of sickness behavior followed by chronic depressive-like behavior. Brain Behav Immun (2008) 1.30
Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer (2009) 1.29
Cancer-related fatigue--mechanisms, risk factors, and treatments. Nat Rev Clin Oncol (2014) 1.29
Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry (2012) 1.28
Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. Br J Cancer (2002) 1.27
Cytokines and cachexia. Nutrition (1997) 1.27
Immune-to-central nervous system communication and its role in modulating pain and cognition: Implications for cancer and cancer treatment. Brain Behav Immun (2003) 1.24
Item and order recognition memory in subjects with hypoxic brain injury. Brain Cogn (1995) 1.24
A critical review of human endotoxin administration as an experimental paradigm of depression. Neurosci Biobehav Rev (2009) 1.24
Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology (2007) 1.23
Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I--an independent prognostic factor. Tumour Biol (2005) 1.21
Cytokine genetic variations and fatigue among patients with breast cancer. J Clin Oncol (2013) 1.21
Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur J Pharmacol (2009) 1.18
Future directions in research on consumer-provider communication and adherence to cancer prevention and treatment. Patient Educ Couns (2003) 1.17
Indoleamine 2,3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge. Horm Behav (2012) 1.15
Inactivation of the cerebral NFkappaB pathway inhibits interleukin-1beta-induced sickness behavior and c-Fos expression in various brain nuclei. Neuropsychopharmacology (2005) 1.15
Alpha-tocopherol attenuates NFkappaB activation and pro-inflammatory cytokine production in brain and improves recovery from lipopolysaccharide-induced sickness behavior. J Neuroimmunol (2005) 1.14
Elevated postoperative inflammatory biomarkers are associated with short- and medium-term cognitive dysfunction after coronary artery surgery. J Anesth (2011) 1.13
Many faces of DAMPs in cancer therapy. Cell Death Dis (2013) 1.11
Induction of inhibitory factor kappaBalpha mRNA in the central nervous system after peripheral lipopolysaccharide administration: an in situ hybridization histochemistry study in the rat. Proc Natl Acad Sci U S A (1997) 1.10
Distant metastases from head and neck squamous cell carcinoma. Part I. Basic aspects. Oral Oncol (2012) 1.10
Peripheral tumors induce depressive-like behaviors and cytokine production and alter hypothalamic-pituitary-adrenal axis regulation. Proc Natl Acad Sci U S A (2009) 1.10
C-reactive protein is related to memory and medial temporal brain volume in older adults. Brain Behav Immun (2011) 1.10